Tanja Fauti

This inventor holds 12 USPTO granted patents and 26 published patent applications, plus 7 CIPO patents and 11 EPO patents. Top assignees: Hoffmann-La Roche Inc., Engmab Sarl, Roche Glycart Ag. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tanja Fauti. Retrieved from https://idiyas.com/inventor/tanja-fauti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 26)

% Patents Active = 83.3

CIPO Patents = 7 (Patent Applications = 7)

EPO Patents = 11 (Patent Applications = 27)

Average Co-Inventor Count = 9.5

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Zürich, CH (2018)
Schlieren, CH (2023)
Zurich, CH (2018 - 2024)

Company Filing History:

4 out of 5,026

Hoffmann-La Roche Inc.

Bristol-Myers Squibb Compnay

Years Active: 2018-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715923 - ANTIBODIES BINDING TO GPRC5D (2026-08-25),

2. 12600781 - TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES (2026-04-14),

3. 11987632 - Antibodies binding to HLA-A2/MAGE-A4 (2024-05-21),

4. 11952421 - Bispecific antibodies against CD3EPSILON and ROR1 (2024-04-09),

5. 11639397 - Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use (2023-05-02),

6. 11608376 - Tumor-targeted agonistic CD28 antigen binding molecules (2023-03-21),

7. 10851171 - Method for the selection of antibodies against BCMA (2020-12-01),

8. 10766967 - Bispecific T cell activating antigen binding molecules (2020-09-08),

9. 10253104 - Bispecific antibodies against CD3ϵ and BCMA (2019-04-09),

10. 10087250 - Fc-free antibodies comprising two fab-fragments and methods of use (2018-10-02),

11. 10077315 - Bispecific antibodies against CD3 and BCMA (2018-09-18),

12. 9963513 - Method for the selection of antibodies against BCMA (2018-05-08),

Title: Tanja Fauti: A Trailblazer in Antibody Innovation

Introduction

Tanja Fauti is an accomplished inventor based in Zurich, Switzerland, renowned for her groundbreaking work in the field of antibody development. With an impressive portfolio of 10 patents, her contributions have significantly advanced therapeutic strategies in medical science.

Latest Patents

Among her latest inventions are two notable patents. The first relates to antibodies binding to HLA-A2/MAGE-A4, which encompass multispecific antibodies aimed at activating T cells. This invention also involves polynucleotides that encode these antibodies, alongside vectors and host cells that incorporate these sequences. Furthermore, methods for producing these antibodies and their application in disease treatment are covered in this patent. The second innovation focuses on bispecific antibodies against CD3Epsilon and ROR1, detailing their manufacture and therapeutic use.

Career Highlights

Throughout her career, Tanja has been affiliated with prestigious organizations, including Hoffmann-La Roche Inc. and Engmab Sàrl. Her time at these renowned companies has allowed her to deepen her expertise in antibody technology and translational medicine.

Collaborations

Tanja Fauti has collaborated with notable colleagues in her field, such as Christian Klein and Ekkehard Moessner. These partnerships have fostered innovation and contributed to the advancement of therapeutic applications in immunology.

Conclusion

Tanja Fauti stands out as a prominent inventor in the realm of antibody technologies. Her innovative spirit and dedication to research continue to drive advancements in the medical field, making her contributions invaluable to contemporary science.

Profile summary based on public USPTO records.